Results - IMM-124E Ameliorates Colits, page-5

Immuron's body of evidence that IMM-124E and Travelan are effective at controlling inflammation in the gut, such as in the liver and colon, via the LPS bacterial-endotoxin pathway is really starting to become overwhelming at this point (NASH Phase 2 results, Shigella primate results, colitis animal model results, Passport Health endorsement, Sanyal, Diehl, Rogler, U.S. NIH fully funded trials, Army/Navy involvement, etc.).

And we continue to trade at a $30 million USD market cap w/ only 3.53 million outstanding shares (based on U.S. conversion). When the market finally discovers this, I believe the share price will soar astronomically.